Rezolute, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Rezolute priced 22,040,976 common shares at $3.87/share and 3,800,000 pre-funded warrants at $3.869/warrant, with an exercise price of $0.001/share on the warrants. Gross proceeds approximately $100 million (before underwriting costs). Underwriters: Morgan Stanley, Guggenheim, Cantor (book-runners); H.C. Wainwright, Jones (leads); Maxim, Lake Street (co-managers). Closing expected November 16, 2026. Company intends to use proceeds for ersodetug commercialization, working capital, and general corporate purposes.
Why this rating
~$100M gross proceeds is ~39% of company's $258.8M market cap—material dilution event. However, typical for biotech capital raise at this stage; no M&A, bankruptcy, or transformational change. Moderate significance for company trajectory.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.